FDA Approves Generic Ropinirole Hydrochloride for Treatment of Restless Legs Syndrome
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Generic Ropinirole Hydrochloride for Treatment of Restless Legs Syndrome

ROCKVILLE, Md. -- May 9, 2008 -- The US Food and Drug Administration (FDA) has approved the generic ropinirole hydrochloride (Requip) tablets for the treatment of moderate to severe restless legs syndrome.

Ropinirole hydrochloride tablets have been approved in 0.25-, 0.5-, 1-, 2-, 3-, and 4-mg doses.

The labelling of the generic versions of ropinirole hydrochloride may differ from the brand-name drug because some uses of the medication are protected by patents. In addition to treating restless legs syndrome, the brand-name drug has also been approved by the FDA to treat symptoms of Parkinson's disease. However, the generic version of the medication is not approved for treatment of Parkinson's disease because this indication is protected by patent. Manufacturers of the generic drugs may seek approval for that use once the patent for the Parkinson's disease indication expires later this month.

Ropinirole hydrochloride tablets will have the same safety warnings as the brand-name medication, cautioning about patient reports of falling asleep while engaged in activities of daily living, including while driving.

"This generic drug approval is an example of the FDA's efforts to increase access to safe and effective generic drugs as soon as the law permits," said Gary J. Buehler, Director, FDA, Office of Generic Drugs, Rockville, Maryland.

SOURCE: US Food and Drug Administration

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities